Improving Medicaid Precision and Cancer Test Act of 2025
Summary
H.R. 6320, the "Improving Medicaid Precision and Cancer Test Act of 2025," aims to amend Title XIX of the Social Security Act. The bill mandates Medicaid coverage for lung cancer biomarker testing. This requirement would become effective starting January 1, 2027.
Expected Effects
The bill will expand Medicaid coverage to include lung cancer biomarker testing. This will allow more individuals access to precision medicine for lung cancer treatment. Ultimately, this could improve health outcomes for Medicaid recipients diagnosed with lung cancer.
Potential Benefits
- Increased access to lung cancer biomarker testing for Medicaid recipients.
- Potential for more precise and effective treatment plans.
- Improved health outcomes and survival rates for lung cancer patients.
- Reduced healthcare costs in the long term by avoiding ineffective treatments.
- Alignment with advancements in personalized medicine.
Potential Disadvantages
- Increased short-term costs to the Medicaid program.
- Potential administrative burden for implementation.
- Possible need for additional infrastructure and trained personnel to conduct the tests.
- Risk of overutilization of testing if not properly managed.
- Delayed implementation until 2027 may postpone benefits.
Most Disadvantaged Areas:
Constitutional Alignment
The bill appears to align with the general welfare clause of the Constitution, as it aims to improve public health by expanding access to cancer testing. Article I, Section 8 grants Congress the power to lay and collect taxes, duties, imposts and excises, to pay the debts and provide for the common defense and general welfare of the United States. The expansion of Medicaid falls under the purview of providing for the general welfare.
Impact Assessment: Things You Care About ⓘ
This action has been evaluated across 19 key areas that matter to you. Scores range from 1 (highly disadvantageous) to 5 (highly beneficial).